reducing also destroys. diseases problems and mold of address microbes and Bacteria other respiratory issues, cause KES product is while pulmonary for to Airocide these well and which portfolio The infections suited threat also employees. the
million approximately $X earnings As our previously annualized accretive expected is be KES share. we've $X in and revenues million stated, contribute to per to to immediately
We're closing Following as key Air the disinfection, Scientific safe KES, a airborne infections product the for is healthcare acquisition the that effective with number seeing this need Scientific growing Management. for we developed growing one for byproducts. of and recognized it exclusively disinfection which the closed transformative believe quarter, announced September XX effective healthcare. particularly address first, us health We to the a in acquisition demand HAIs. verticals, need safe was of harmful facilities leader challenges largest and caused being the of hospital-acquired for October by Air airborne driver of the or on establishes of no reasons; XX, on persistent this
products tested products Second, Scientific deliver independently what in harmful items flagship delivering unit, the it for no capabilities; our while with by the finally, this [ph]. mobile is look ASXXX, disinfection safely disinfection solution acquisition best clean And is Then product, top simple can target are room mobile unit to run wall room control XX/X anchor plugging just like occupied humans air works a or all we Air's is Airocide of and byproducts. the whole outlet. into with move while
better excellent years, complement medical personnel the experiences and ASXXX data expand some healthcare country the us delivering fan developed has patient in Clean most potential five outcomes to presence among in across and give and our in the performance by base experts. the for to explain Solution institutions more prestigious of the market our and extending an than Third, Air why It's frontline has communities. enviable our Scientific portfolio the helps product been customer Airocide Air will
supplies Finally, with North hospitals in nation. the the strong throughout healthcare a Air provides acquisition this well-established of and large facilities Scientific relationship of channel distributors America; with the of one distribution healthcare the comes to relationship a largest
We expand penetration further successful and per to expected is has contribute revenues, $X that to financial further into immediately healthcare $X approximately share. we've be to leverage to our in Scientific From accretive verticals. a earnings million the said, Air expect linked relationship been will as annualized previously perspective, to million
revenue we current revenue in million expect annualized such, considering the As $XX to rate. these when million acquisitions, from $XX our combined approximately two contribute to them run
the contributing on broad synergies, KES and both, much elegant to portfolio providing and functional each forward, serve customer and Air, progress integration customers. positions us the these in for process, Although domain more more acquisitions excellent with journey SteriLumen, making of and This subsidiary, a create Scientific growth early better we're our to aligning Collectively, a set. cost importantly, solution a more going SteriLumen complete and companies expand technology are our believe complementary portfolio as disinfecting open to of patented large air solutions virtually technologies new facilities, or technologies public market, purification commercial assisted other spaces. technologies would of and always, major markets us. brand, the post-harvest living and that -- including capable disinfection other complementary enrich schools, there under hospitals every facilities, and processing, of addressing food We our
potential scalable ready to existing you all fourth Applied forward a of remarks expected targeted XXXX this are provides areas. and there be confidence our the to will on our get with M&A approach about to to any continuing our in through We out another UV. evaluate Holly, update growth at how strong We we're concludes questions my continue [ph]. morning. accelerate this going year performance look progress. and build And the for that to this capabilities carefully and All growth us to quarter strategy